TY - JOUR AU - Li Heng AU - Yang Li AU - Liu Fei-fei AU - Ma Xin-na AU - He Pei-lan AU - Tang Wei AU - Tong Xian-kun AU - Zuo Jian-ping PY - 2020 TI - Overview of therapeutic drug research for COVID-19 in China JF - Acta Pharmacologica Sinica; Vol 41, No 9 (September 2020): Acta Pharmacologica Sinica Y2 - 2020 KW - N2 - Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS- CoV-2 agents are also reviewed. UR - http://www.chinaphar.com/article/view/10190